D-LINE CATHETER ST, DOUBLE LUMEN ST; EXTRA FLOW

K063355 · Novosci Corp. · MPB · Jul 27, 2007 · Gastroenterology, Urology

Device Facts

• Record ID: K063355
• Device Name: D-LINE CATHETER ST, DOUBLE LUMEN ST; EXTRA FLOW
• Applicant: Novosci Corp.
• Product Code: MPB · Gastroenterology, Urology
• Decision Date: Jul 27, 2007
• Decision: SESK
• Submission Type: Traditional
• Regulation: 21 CFR 876.5540
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Dual Lumen Short Term Hemodialysis and Extra Flow (EF) Short Term Hemodialysis catheters are indicated for use in hemodialysis, hemoperfusion and apheresis for short-term duration of less than 30 days via the subclavian, femoral or jugular vein.

Device Story

Polyurethane radiopaque catheter for hemodialysis, hemoperfusion, and apheresis; features double 'D' lumen configuration for arterial and venous flow. Extra Flow (EF) design includes venous lumen extending beyond arterial lumen with round tip; Dual Lumen design includes side-holes. Includes color-coded safety clamps (red/blue) with priming volume/length data and swiveling suture ring for securement. Kit includes guidewire, introducer needle, dilator, and luer lock caps. Used by clinicians in clinical settings for short-term vascular access. Provides conduit for blood flow during extracorporeal therapy; facilitates patient treatment by enabling necessary blood purification procedures.

Clinical Evidence

Bench testing only. Engineering studies performed in accordance with FDA guidance for short-term intravascular catheters and coronary/cerebrovascular guidewires, ISO 10555 (sterile, single-use intravascular catheters), and ISO 10993 (biological evaluation).

Technological Characteristics

Polyurethane radiopaque material; double 'D' lumen shaft configuration; color-coded safety clamps; swiveling suture ring. Complies with ISO 10555 and ISO 10993. Sterilization method not specified. Standalone device.

Indications for Use

Indicated for patients requiring hemodialysis, hemoperfusion, or apheresis for short-term duration (<30 days) via subclavian, femoral, or jugular venous access.

Regulatory Classification

Identification

A blood access device and accessories is a device intended to provide access to a patient's blood for hemodialysis or other chronic uses. When used in hemodialysis, it is part of an artificial kidney system for the treatment of patients with renal failure or toxemic conditions and provides access to a patient's blood for hemodialysis. The device includes implanted blood access devices, nonimplanted blood access devices, and accessories for both the implanted and nonimplanted blood access devices.(1) The implanted blood access device is a prescription device and consists of various flexible or rigid tubes, such as catheters, or cannulae, which are surgically implanted in appropriate blood vessels, may come through the skin, and are intended to remain in the body for 30 days or more. This generic type of device includes various catheters, shunts, and connectors specifically designed to provide access to blood. Examples include single and double lumen catheters with cuff(s), fully subcutaneous port-catheter systems, and A-V shunt cannulae (with vessel tips). The implanted blood access device may also contain coatings or additives which may provide additional functionality to the device. (2) The nonimplanted blood access device consists of various flexible or rigid tubes, such as catheters, cannulae or hollow needles, which are inserted into appropriate blood vessels or a vascular graft prosthesis (§§ 870.3450 and 870.3460), and are intended to remain in the body for less than 30 days. This generic type of device includes fistula needles, the single needle dialysis set (coaxial flow needle), and the single needle dialysis set (alternating flow needle). (3) Accessories common to either type include the shunt adaptor, cannula clamp, shunt connector, shunt stabilizer, vessel dilator, disconnect forceps, shunt guard, crimp plier, tube plier, crimp ring, joint ring, fistula adaptor, and declotting tray (including contents).

Special Controls

*Classification.* (1) Class II (special controls) for the implanted blood access device. The special controls for this device are:(i) Components of the device that come into human contact must be demonstrated to be biocompatible. Material names and specific designation numbers must be provided. (ii) Performance data must demonstrate that the device performs as intended under anticipated conditions of use. The following performance characteristics must be tested: (A) Pressure versus flow rates for both arterial and venous lumens, from the minimum flow rate to the maximum flow rate in 100 milliliter per minute increments, must be established. The fluid and its viscosity used during testing must be stated. (B) Recirculation rates for both forward and reverse flow configurations must be established, along with the protocol used to perform the assay, which must be provided. (C) Priming volumes must be established. (D) Tensile testing of joints and materials must be conducted. The minimum acceptance criteria must be adequate for its intended use. (E) Air leakage testing and liquid leakage testing must be conducted. (F) Testing of the repeated clamping of the extensions of the catheter that simulates use over the life of the device must be conducted, and retested for leakage. (G) Mechanical hemolysis testing must be conducted for new or altered device designs that affect the blood flow pattern. (H) Chemical tolerance of the device to repeated exposure to commonly used disinfection agents must be established. (iii) Performance data must demonstrate the sterility of the device. (iv) Performance data must support the shelf life of the device for continued sterility, package integrity, and functionality over the requested shelf life that must include tensile, repeated clamping, and leakage testing. (v) Labeling of implanted blood access devices for hemodialysis must include the following: (A) Labeling must provide arterial and venous pressure versus flow rates, either in tabular or graphical format. The fluid and its viscosity used during testing must be stated. (B) Labeling must specify the forward and reverse recirculation rates. (C) Labeling must provide the arterial and venous priming volumes. (D) Labeling must specify an expiration date. (E) Labeling must identify any disinfecting agents that cannot be used to clean any components of the device. (F) Any contraindicated disinfecting agents due to material incompatibility must be identified by printing a warning on the catheter. Alternatively, contraindicated disinfecting agents must be identified by a label affixed to the patient's medical record and with written instructions provided directly to the patient. (G) Labeling must include a patient implant card. (H) The labeling must contain comprehensive instructions for the following: ( *1* ) Preparation and insertion of the device, including recommended site of insertion, method of insertion, and a reference on the proper location for tip placement;( *2* ) Proper care and maintenance of the device and device exit site;( *3* ) Removal of the device;( *4* ) Anticoagulation;( *5* ) Management of obstruction and thrombus formation; and( *6* ) Qualifications for clinical providers performing the insertion, maintenance, and removal of the devices.(vi) In addition to Special Controls in paragraphs (b)(1)(i) through (v) of this section, implanted blood access devices that include subcutaneous ports must include the following: (A) Labeling must include the recommended type of needle for access as well as detailed instructions for care and maintenance of the port, subcutaneous pocket, and skin overlying the port. (B) Performance testing must include results on repeated use of the ports that simulates use over the intended life of the device. (C) Clinical performance testing must demonstrate safe and effective use and capture any adverse events observed during clinical use. (vii) In addition to Special Controls in paragraphs (b)(1)(i) through (v) of this section, implanted blood access devices with coatings or additives must include the following: (A) A description and material characterization of the coating or additive material, the purpose of the coating or additive, duration of effectiveness, and how and where the coating is applied. (B) An identification in the labeling of any coatings or additives and a summary of the results of performance testing for any coating or material with special characteristics, such as decreased thrombus formation or antimicrobial properties. (C) A Warning Statement in the labeling for potential allergic reactions including anaphylaxis if the coating or additive contains known allergens. (D) Performance data must demonstrate efficacy of the coating or additive and the duration of effectiveness. (viii) The following must be included for A-V shunt cannulae (with vessel tips): (A) The device must comply with Special Controls in paragraphs (b)(1)(i) through (v) of this section with the exception of paragraphs (b)(1)(ii)(B), (b)(1)(ii)(C), (b)(1)(v)(B), and (b)(1)(v)(C), which do not apply. (B) Labeling must include Warning Statements to address the potential for vascular access steal syndrome, arterial stenosis, arterial thrombosis, and hemorrhage including exsanguination given that the device accesses the arterial circulation. (C) Clinical performance testing must demonstrate safe and effective use and capture any adverse events observed during clinical use. (2) Class II (performance standards) for the nonimplanted blood access device. (3) Class II (performance standards) for accessories for both the implanted and the nonimplanted blood access devices not listed in paragraph (b)(4) of this section. (4) Class I for the cannula clamp, disconnect forceps, crimp plier, tube plier, crimp ring, and joint ring, accessories for both the implanted and nonimplanted blood access device. The devices subject to this paragraph (b)(4) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.

Predicate Devices

• Kendall Mahurkar Catheter (K963446)
• Kendall Mahurkar QPlus Catheter (K030209)
• Medcomp Duo-flow Catheter (K974236)

Submission Summary (Full Text)

{0}------------------------------------------------

## 510(k) Summary

# JUL 27 2007

## 1. Contact Information

| Submitter: | NovoSci, Inc.<br>2828 N. Crescent Ridge Drive<br>The Woodlands, TX 77381 |
|-----------------|--------------------------------------------------------------------------|
| | 405.826.0713 Phone<br>888.795.1609 Fax |
| Contact Person: | David Makanani |
| Date Prepared: | 4/13/2007 |

## 2. Device Names

| Trade: | Joline D-Line Catheter ST family of catheters in kits consisting of<br>• Dual Lumen Short Term Hemodialysis Catheter<br>• Extra Flow (EF) Short Term Hemodialysis Catheter |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Common Name: | Hemodialysis Short Term Catheter |
| Classification Name: | 78 MPB - Catheter, Hemodialysis, Non-implanted<br>21 CFR 876.5540 (b)(2) |

## 3. Predicate Device

Kendall Mahurkar Catheter, K963446 Kendall Mahurkar QPlus Catheter, K030209 Medcomp Duo-flow Catheter, K974236

## 4. Description of Device

The Joline D-Line Catheter ST family of catheters, consisting of the Dual Lumen Short Term Hemodialysis and Extra Flow (EF) Short Term Hemodialysis catheters are a polyurethane radiopaque catheter which allows for hemodialysis, hemoperfusion and apheresis. A crosssectional view of the shaft of the Joline D-Line Catheter ST catheters reveals a double "D" configuration -one "D" for the arterial lumen and the other for the venous lumen. In the Extra Flow (EF) Short Term design the venous lumen extends beyond the arterial lumen and terminates in a round tip. The Dual Lumen Short Term catheter has both lumens exiting together and incorporates side-holes along the shaft of the catheter body in its design.

Two color-coded safety clamps, red and blue, identify arterial and venous extensions. lmportant information such as priming volume and catheter length is printed on both sides of the clamp. A swiveling suture ring is available to secure the catheter after placement.

{1}------------------------------------------------

Two extensions merge into a tapered bifurcation joint or hub molded to the catheter body. These extensions can be straight, curved or curved-to-one-side.

The finished kit consists of either the Dual Lumen Short Term Hemodialysis or Extra Flow ITIc Timenta Kit of Childers packaged with various accessory components. These components include: guidewire, introducer needle, dilator, and luer lock caps. I need "componently "rictions for use for the various accessories, where appropriate.

#### 5. Indications for Use

The Dual Lumen Short Term Hemodialysis and Extra Flow (EF) Short Term Hemodialysis catheters are indicated for use in hemodialysis, hemoperfusion and apheresis for short-term duration of less than 30 days via the subclavian, femoral or jugular vein

#### 6. Comparison to Predicate Device

The Dual Lumen Short Term Hemodialysis and Extra Flow (EF) Short Term Hemodialysis catheters are substantially equivalent to the Kendall Tyco Mahurkar, Kendall Tyco Mahurkar QPlus, and the Medcomp Duo-Flow Catheters.

A close examination of specifications reveals that there are no major differences in design, materials, performance, biocompatibility, safety and product effectiveness. Supporting information in the form of engineering bench testing has been provided.

## 7. Non-clinical Performance Tests:

Engineering studies were performed to FDA's "Guidance on Premarket Notification 510(k) Submissions for Short Term and Long Term Intravascular Catheters", and "Coronary and Cerebrovascular Guidewire Guidance", ISO 10555 - International standard for "Sterile, Single-Use, Intravascular Catheters, ISO 10993 - International standard for "Biological Evaluation of Medical Devices", and additional test requirements for hemodialysis catheters.

## 8. Conclusion

The Dual Lumen Short Term Hemodialysis and Extra Flow (EF) Short Term Hemodialysis catheters were demonstrated to be substantially equivalent to the predicate devices based on its design, test results, and indications for use.

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle with three lines representing its body and three curved lines representing its legs. The eagle is facing to the right. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the eagle.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

JUL 2 7 2007

Mr. David Makanani Vice President NovoSci"* 2828 North Crescent Ridge Drive THE WOODLANDS TX 77381

Re: K063355

Trade/Device Name: Joline D-Line Catheter ST family of catheters consisting of the

- Dual Lumen Short Term Hemodialysis catheter .
- Extra Flow (EF) Short Term Hemodialysis catheter .

Regulation Number: 21 CFR §876.5540 Regulation Name: Blood access device and accessories Regulatory Class: III Product Code: MPB Dated: July 20, 2007 Received: July 23, 2007

Dear Mr. Makanani:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. However, you are responsible to determine that the medical devices you use as components in the kit have either been determined as substantially equivalent under the premarket notification process (Section 510(k) of the act), or were legally on the market prior to May 28, 1976, the enactment date of the Medical Device Amendments. Please note: If you purchase your device components in bulk (i.e., unfinished) and further process (e.g., sterilize) you must submit a new 510(k) before including these components in your kit. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, and labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{3}------------------------------------------------

## Page 2 - Mr. David Makanani

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration (21 CFR Part 807); listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on the labeling regulation, please contact the Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll free number [phone] or [phone], or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Arput Mnhng fancs

ancy C. Brogdon Director, Division of Reproductive, Abdominal, and Radiological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

## Indications for Use

510(k) Number (if known): ____________________________________________________________________________________________________________________________________________________

Device Name: _The Joline D-Line Catheter ST family of catheters consisting of the

- Dual Lumen Short Term Hemodialysis catheter .
- Extra Flow (EF) Short Term Hemodialysis catheter ●

Indications for Use:

The Dual Lumen Short Term Hemodialysis and Extra Flow (EF) Short Term Hemodialysis catheters are indicated for use in hemodialysis, hemoperfusion and apheresis for short-term duration of less than 30 days via the subclavian, femoral or jugular vein.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription Use (Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use (21 CFR 801 Subpart C)

Ame M. Wz
(Division Sign-Off)

(Divisi Division of Reproductive, Abdominal and Radiological Devices 510(k) Number